



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Operations Office

TO: Primary Clinical Research Associates

FROM: Sara Braun
Research Protocol Specialist III

DATE: April 16, 2010

SUBJECT: N0272, Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma

The Nadir/Adverse Event Log has been revised as follows:

CRF Title	Brief Description of Edit
Nadir/Adverse Event Log	<ul style="list-style-type: none">Added "CTCAE v. 2.0" to Adverse Event on all 3 pages.

If you have any questions, please feel free to contact me at 507/538-8226.

Thank you.